Hilton Capital Management LLC Sells 1,870 Shares of Eli Lilly and Company (NYSE:LLY)

Hilton Capital Management LLC decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 11.0% in the fourth quarter, Holdings Channel reports. The fund owned 15,200 shares of the company’s stock after selling 1,870 shares during the quarter. Eli Lilly and Company makes up 1.0% of Hilton Capital Management LLC’s holdings, making the stock its 28th biggest holding. Hilton Capital Management LLC’s holdings in Eli Lilly and Company were worth $11,734,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in LLY. Principal Financial Group Inc. lifted its holdings in shares of Eli Lilly and Company by 5.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock valued at $1,070,698,000 after acquiring an additional 60,306 shares during the last quarter. GSA Capital Partners LLP bought a new stake in Eli Lilly and Company in the third quarter worth about $606,000. Haverford Trust Co lifted its stake in Eli Lilly and Company by 0.9% in the third quarter. Haverford Trust Co now owns 3,515 shares of the company’s stock worth $3,114,000 after purchasing an additional 31 shares during the last quarter. Schrum Private Wealth Management LLC bought a new stake in Eli Lilly and Company in the third quarter worth about $312,000. Finally, Bell Bank lifted its stake in Eli Lilly and Company by 1.6% in the third quarter. Bell Bank now owns 1,492 shares of the company’s stock worth $1,322,000 after purchasing an additional 23 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

Shares of LLY opened at $798.39 on Friday. The company has a market cap of $757.01 billion, a price-to-earnings ratio of 68.18, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a twelve month low of $711.40 and a twelve month high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The company has a 50 day moving average of $830.18 and a two-hundred day moving average of $844.96.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its board has approved a stock buyback program on Monday, December 9th that authorizes the company to buyback $15.00 billion in shares. This buyback authorization authorizes the company to purchase up to 2% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

Several analysts have issued reports on LLY shares. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Citigroup decreased their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Morgan Stanley set a $1,146.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, March 6th. Wolfe Research started coverage on shares of Eli Lilly and Company in a research report on Friday, November 15th. They set an “outperform” rating and a $1,000.00 target price on the stock. Finally, Berenberg Bank set a $970.00 target price on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $1,009.72.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.